Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome.

Vaiva G, Thomas P, Llorca PM, Dupont S, Cottencin O, Devos P, Mazas O, Rascle C, Steinling M, Goudemand M.

Psychiatry Res. 2002 Aug 20;115(1-2):37-48.

PMID:
12165366
2.

[Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature].

Pélissolo A, Krebs MO, Olié JP.

Encephale. 1996 May-Jun;22(3):215-9. Review. French.

PMID:
8767050
3.

Clinical update on amisulpride in deficit schizophrenia.

Rein W, Turjanski S.

Int Clin Psychopharmacol. 1997 May;12 Suppl 2:S19-27. Review.

PMID:
9218164
4.

[Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].

Chabannes JP, Pelissolo A, Farah S, Gerard D.

Encephale. 1998 Jul-Aug;24(4):386-92. French.

PMID:
9809244
5.
6.

The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.

Herrera-Estrella M, Apiquian R, Fresan A, Sanchez-Torres I.

BMC Psychiatry. 2005 May 3;5:22.

7.

Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine.

Saletu B, Küfferle B, Grünberger J, Földes P, Topitz A, Anderer P.

Neuropsychobiology. 1994;29(3):125-35.

PMID:
7912819
8.

D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.

la Fougère C, Meisenzahl E, Schmitt G, Stauss J, Frodl T, Tatsch K, Hahn K, Möller HJ, Dresel S.

J Nucl Med. 2005 Jun;46(6):1028-33.

9.

Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.

Zink M, Knopf U, Henn FA, Thome J.

Pharmacopsychiatry. 2004 Jan;37(1):26-31. Review.

PMID:
14750045
10.

Treatment of negative symptoms in schizophrenia with amisulpride.

Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F.

Br J Psychiatry. 1995 Jan;166(1):68-72.

PMID:
7894879
11.
12.

Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.

Bressan RA, Erlandsson K, Spencer EP, Ell PJ, Pilowsky LS.

Psychopharmacology (Berl). 2004 Sep;175(3):367-73.

PMID:
14997280
13.

Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.

Freeman HL.

Int Clin Psychopharmacol. 1997 May;12 Suppl 2:S11-7. Review.

PMID:
9218163
14.

Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.

Müller MJ, Regenbogen B, Härtter S, Eich FX, Hiemke C.

J Psychiatr Res. 2007 Oct;41(8):673-9. Epub 2005 Dec 1.

PMID:
16324716
15.

Improvement of some schizophrenic deficit symptoms with low doses of amisulpride.

Paillère-Martinot ML, Lecrubier Y, Martinot JL, Aubin F.

Am J Psychiatry. 1995 Jan;152(1):130-4.

PMID:
7802104
17.

Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?

Blin O.

Encephale. 2000 Oct;26 Spec No 1:7-11. Review. English, French.

PMID:
11294060
18.

Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride.

Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kühn KU.

Neuropsychopharmacology. 2005 Feb;30(2):381-90.

19.

Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study.

Kim SW, Shin IS, Kim JM, Yang SJ, Hwang MY, Yoon JS.

J Clin Psychopharmacol. 2008 Jun;28(3):349-52. doi: 10.1097/JCP.0b013e318172755a. No abstract available.

PMID:
18480697
20.

Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients.

Trichard C, Paillère-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL.

Am J Psychiatry. 1998 Apr;155(4):505-8.

PMID:
9545996

Supplemental Content

Support Center